P21 (P021)

P21 (also P021) is a synthetic peptide mimetic derived from ciliary neurotrophic factor (CNTF), designed to retain CNTF's neurotrophic and neurogenic effects while improving bioavailability and reducing the side effect profile that limited full-length CNTF development. It is researched for hippocampal neurogenesis, cognitive preservation, and neuroprotection in neurodegenerative models. P21 is not approved for any medical indication and is in preclinical and early translational research contexts. The compound is among the newest additions to the Peptigrity catalog and the broader research-peptide market.

What is P21 and how does the CNTF-mimetic mechanism work?

P21 is a synthetic peptide mimetic derived from a specific active region of ciliary neurotrophic factor (CNTF), designed to retain CNTF's neurotrophic and neurogenic effects (BDNF pathway activation, hippocampal neurogenesis stimulation) while improving pharmacokinetics relative to full-length CNTF, which faced clinical development challenges due to side effects including weight loss and immune responses. The compound is mechanistically positioned to support adult neurogenesis in age-related and disease-related cognitive decline contexts.

Evidence level: preclinical (rodent cognition, hippocampal neurogenesis); no published human clinical trials

What does the research show for P21?

Preclinical rodent studies have demonstrated effects on hippocampal neurogenesis, cognitive performance in aging and neurodegenerative models (including Alzheimer's-relevant tauopathy models), and BDNF pathway activation. The research originates predominantly from Khalid Iqbal's group at the New York State Institute for Basic Research, with mechanistic studies and animal model efficacy data published in peer-reviewed journals. Human clinical evidence is absent.

Source: Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease, Kazim S.F., Blanchard J., Dai C.-L., Tung Y.-C., LaFerla F.M., Grundke-Iqbal I., Iqbal K., Neurobiology of Disease, 2014 · Evidence level: preclinical (rodent, multiple models); no human clinical trials

How does P21 compare to other cognitive/neuroprotective peptides?

P21 is among the newest preclinical-stage cognitive peptides in research-grade markets, with mechanism positioning toward neurogenesis rather than neurotransmitter modulation or microtubule stabilization.

What are the documented side effects of P21?

Human safety data for P21 is essentially absent — no published Phase 1 or later trials. Preclinical rodent studies have not surfaced significant toxicity signals at researched doses. The CNTF-derived nature could theoretically carry some of the parent compound's side effect liabilities (weight loss, immune responses), but the mimetic design was specifically aimed at reducing these. Long-term safety in humans is completely unknown.

Evidence level: preclinical safety only; no human safety data

What is the regulatory status of P21?

P21 is not approved for any medical indication anywhere in the world as of August 2026. No active human clinical trial program has been registered for P21. The compound is sold strictly as a research-use-only material by third-party laboratories. Buyers should treat P21 as an extremely early-stage research compound with promising preclinical signals but no human evidence. Regulatory context in are peptides legal regulatory status by country.

Why does P21 vendor verification matter for an early-stage compound?

Because P21 is among the newest compounds in research-grade markets, vendor synthesis quality control may be variable, and the relatively niche demand means fewer laboratories have optimized production. Independent HPLC purity testing and mass spectrometry identity confirmation are essential. The newness of the compound also means buyers should be alert to potential mislabeling or substitution. Guidance in how-to-test-peptides hub.

How does Peptigrity verify P21 vendors?

Peptigrity collects independent third-party Certificates of Analysis for P21 from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does P21 do?

P21 is researched for hippocampal neurogenesis and cognitive preservation through CNTF-derived neurotrophic mechanism activity, with preclinical evidence in rodent aging and neurodegenerative models. Human clinical evidence is absent.

Is P21 legal to purchase?

P21 is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.

Will P21 be FDA-approved?

No active FDA clinical development program for P21 exists as of August 2026. The compound remains in preclinical research stage.

How does P21 compare to other neurogenic compounds?

P21's CNTF-derived mechanism targets hippocampal neurogenesis specifically, distinguishing it from broader neuroprotective compounds like Semax (multi-system) or microtubule-targeted compounds like Adamax/Davunetide. Direct comparisons are limited by the absence of human efficacy data for P21.

How can I verify a P21 vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. The compound's relative newness in research-grade markets makes verification particularly important. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a P21 dose?

No. P21 has no published human clinical data, is not approved for human consumption, and Peptigrity is an independent review platform, not a medical authority. Translation from rodent dosing to human use is highly uncertain. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. P21 (P021) is not approved by the FDA or any other regulator for human use and has no published human clinical trial data. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.